ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The broad-spectrum tyrosine kinase inhibitor (TKI) dasatinib was originally developed to target breakpoint cluster region-Abelson tyrosine-protein kinase 1 (BCR-Abl) and is now widely used in the treatment of chronic myeloid leukemia (CML) [14–17].